GTS-21 is an investigational drug.
There have been 10 clinical trials for GTS-21.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2022.
The most common disease conditions in clinical trials are Schizophrenia, Tourette Syndrome, and Syndrome. The leading clinical trial sponsors are VA Office of Research and Development, University of Colorado, Denver, and CoMentis.
There are twenty-three US patents protecting this investigational drug and two hundred and fifty-two international patents.